In-Vivo CAR-T Enters Neurologic Autoimmunity
A peer-reviewed New England Journal of Medicine letter reports first-in-patient feasibility for a T-cell-targeted, non-replicating self-inactivating lentiviral vector that generates CD19 CAR-T cells directly in vivo. Sixteen patients with treatment-refractory neurologic autoimmune disease received…
